Anastrozole
Her2-Receptor Negative Breast Cancer
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07391774CT.gov Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | — | Recruiting | — | — | — |
NCT07483307CT.gov A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | — | Recruiting | — | — | — |
NCT06953882CT.gov Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy | — | Recruiting | — | — | — |
NCT06179303CT.gov Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05512364CT.gov Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | — | Recruiting | — | — | — |
NCT06016738CT.gov OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05190094CT.gov Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. | — | Recruiting | — | — | — |
NCT05467891CT.gov Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05524584CT.gov Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05362760CT.gov Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management | — | Recruiting | — | — | — |
Show 11 more trialsShow fewer
NCT04985266CT.gov A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT03554044CT.gov T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | — | Completed | — | — | — |
NCT03691493CT.gov Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | — | Completed | — | — | — |
NCT02760030CT.gov Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02894398CT.gov Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | — | Completed | — | — | — |
NCT02648477CT.gov Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02269670CT.gov Phase II Study of Everolimus Beyond Progression | — | Terminated | — | — | — |
NCT01776008CT.gov Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer | — | Terminated | — | — | — |
NCT01368263CT.gov Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | — | Terminated | — | — | — |
NCT01394211CT.gov Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | — | Terminated | — | — | — |
NCT01234532CT.gov Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Her2-Receptor Negative Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anastrozole (this asset) | National Cancer Institute (NCI) | Approved | BB · 64 |
| Palbociclib | Helwan University | P2 | BBB |
| Exemestane | National Cancer Institute (NCI) | P4 | BBB |
| Pembrolizumab | UNC Lineberger Comprehensive Cancer Center | P2 | BBB |
| Atezolizumab | TransThera Sciences (Nanjing), Inc. | P2 | BB |
| Docetaxel | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P2/3 | BB |
| Palazestrant | Olema Pharmaceuticals, Inc. | P3 | BB |
| Capecitabine | Kristina A. Fanucci | P4 | BB |
| Durvalumab | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Her2-Receptor Negative Breast Cancer cohort
Other indications for Anastrozole
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 74 |
| Hypogonadotropic Hypogonadism | — | P4 | BBB · 73 |
| Invasive Breast Carcinoma | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Anastrozole in Her2-Receptor Negative Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/anastrozole-her2-receptor-negative-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →